From GlobeNewswire: 2025-05-13 16:01:00

Biodesix, Inc. reported a total Q1 2025 revenue of $18.0 million, marking a 21% increase over Q1 2024. Gross margins for Q1 2025 were 79.4%, with a net loss improvement of 18% compared to the previous year. The company updated its 2025 revenue guidance to a range of $80-85 million. A conference call and webcast will be held today at 4:30 p.m. ET.

The first quarter ended March 31, 2025, saw Biodesix achieve a total revenue of $18.0 million, a 21% increase over the same period in 2024. Diagnostic Testing revenue reached $16.3 million, a rise of 18%, driven by increased total tests delivered. The company also noted an increase in Development Services revenue to $1.7 million, a 61% increase over the prior year. Gross margins were reported at 79.4%, with a net loss improvement of 18% and an 11% improvement in Adjusted EBITDA over the previous year.

Biodesix conducted a successful commercial pilot in the second half of 2024 to expand its commercial reach into pulmonology and primary care physicians’ referral network. The company then reconfigured its sales team structure and revised its revenue guidance for 2025 to $80-85 million due to delays in sales rep hiring and field implementation. Adjusted EBITDA positivity is expected in the fourth quarter of 2025.

Adjusted EBITDA is a key performance measure used by Biodesix management to assess financial performance. The company believes it provides a comparable overview of operations across historical periods. Adjusted EBITDA excludes certain items to provide a measure of operating performance. Biodesix reported a net loss of $11.1 million for Q1 2025 and an Adjusted EBITDA loss of $6.2 million.

Biodesix, Inc. announced a total Q1 2025 revenue of $18.0 million, reflecting a 21% increase over the previous year. The company’s gross margins for Q1 2025 were 79.4%, with a net loss improvement of 18%. Revenue guidance for 2025 has been updated to a range of $80-85 million. The company is set to hold a conference call and webcast today at 4:30 p.m. ET.



Read more at GlobeNewswire:: Biodesix Announces First Quarter 2025 Results and